In April 2025, the WHO unveiled a global repository for National Essential Medicines Lists (nEMLs), aiming to harmonize and improve access to essential medicines, including budesonide. (who.int) This initiative is expected to streamline procurement processes and ensure consistent availability of essential medicines worldwide.
In February 2025, the WHO published a feature story highlighting the expansion of biosimilars, including those for essential biologic therapies. (who.int) This development is pertinent to the budesonide market, as biosimilar competition can influence pricing and availability.
In March 2025, the WHO announced the opening of the application period for the 2025 update of the WHO Model Lists of Essential Medicines. (who.int) This process allows for the inclusion of new medicines and the reevaluation of existing ones, potentially impacting the status of budesonide on the list.
In May 2025, the WHO's 25th Expert Committee on Selection and Use of Essential Medicines convened to review and update the Model List of Essential Medicines. (who.int) The outcomes of this meeting may influence the global positioning and utilization of budesonide in treatment protocols.
In February 2026, the WHO published the Department of Regulation and Prequalification 2025 annual report, detailing regulatory advancements and prequalification activities that impact the approval and distribution of medicines like budesonide. (who.int) This report provides insights into the evolving regulatory landscape affecting pharmaceutical exports.
These developments underscore the dynamic nature of the pharmaceutical industry and the importance of staying informed about regulatory changes and market trends affecting budesonide exports from India.
